Amphista Therapeutics Receives FDA Clearance for AMX-883 AML Trial
CAMBRIDGE, UK, June 8, 2026 Amphista Therapeutics announced that the U.S. Food and Drug Administration (FDA) has cleared the...
targeted protein degradation
Advertisement
Nurix Shows Promising CSU Data for Bexobrutideg
BRISBANE, Calif., May 14, 2026 Nurix Therapeutics presented new preclinical and Phase 1 translational data at the Society for...
Nurix Therapeutics Showcases Bexobrutideg Data at EHA
BRISBANE, Calif., May 12, 2026 Nurix Therapeutics announced that updated clinical data for its investigational BTK degrader bexobrutideg (NX-5948)...
Rigel Expands Oncology Portfolio With VEPPANU Licensing Deal
SOUTH SAN FRANCISCO, Calif., May 12, 2026 Rigel Pharmaceuticals has entered into an exclusive global licensing agreement with Arvinas...
Amphista Targeted Glue Data Shows Tumor Regression
CAMBRIDGE, UK, April 24, 2026 Amphista Therapeutics has unveiled new preclinical data demonstrating the therapeutic potential of its SMARCA2...
Advertisements
Kymera-Gilead Deal Advances CDK2 Cancer Therapy
WATERTOWN, Massachusetts, April 9, 2026 Kymera Therapeutics has announced that Gilead Sciences has exercised its option to exclusively license...
C4 and Roche Expand DAC Cancer Drug Collaboration
WATERTOWN, Mass., April 09, 2026 C4 Therapeutics, Inc. has announced a major expansion of its long-term collaboration with Roche,...
Orum Appoints Chad May to Advance DAC Drug Innovation
BOSTON and DAEJEON, South Korea, Jan. 4, 2026 — Orum Therapeutics, a biotechnology company pioneering degrader-antibody conjugates (DACs), announced...
Bexobrutideg Shows Strong Phase 1 Results in WM Trial
BRISBANE, Calif., December 8, 2025 — Nurix Therapeutics has announced compelling new Phase 1 clinical data for its investigational...
Advertisement
